Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
This study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin). The PubMed, Web of Science, and National Library of Me...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2024-09-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/71/9/71_EJ24-0168/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591901349380096 |
|---|---|
| author | Yuan-Yuan Xu Xu Wang Yu-Qing She Jie Liu Qing Zhang |
| author_facet | Yuan-Yuan Xu Xu Wang Yu-Qing She Jie Liu Qing Zhang |
| author_sort | Yuan-Yuan Xu |
| collection | DOAJ |
| description | This study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin). The PubMed, Web of Science, and National Library of Medicine databases were systematically searched from their inception until December 1, 2023. A meta-analysis was performed using Stata 15.1 software. A total of 12 studies with 13 outcome measures were included. The meta-analysis results revealed that liraglutide significantly reduced body mass index (mean difference [MD] = –1.06, 95%CI: –1.41, –0.70, p < 0.001), triglycerides (MD = –0.35, 95%CI: –0.61, –0.09, p = 0.0009), visceral adipose tissue (MD = –21.06, 95%CI: –34.58, –7.55, p = 0.002), and subcutaneous adipose tissue (MD = –20.53, 95%CI: –29.15, –11.90, p < 0.001) levels in patients with T2DM and NAFLD. Of the 11 studies, 2 reported the occurrence of adverse reactions, which were primarily gastrointestinal. Compared with placebo and other drugs (e.g., insulin), liraglutide may improve glucose metabolism, lipid and liver function parameters, and visceral and subcutaneous fat in patients with T2DM and NAFLD, thus constituting an effective treatment for these patients. |
| format | Article |
| id | doaj-art-40c4d067b788466a8c9c2719d835bd5d |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-40c4d067b788466a8c9c2719d835bd5d2025-01-22T05:20:11ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402024-09-0171988189410.1507/endocrj.EJ24-0168endocrjMeta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver diseaseYuan-Yuan Xu0Xu Wang1Yu-Qing She2Jie Liu3Qing Zhang4First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210046, ChinaFirst Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210046, ChinaEndocrine Department, Nanjing Pukou People’s Hospital, Nanjing 211899, ChinaLiuzhou Traditional Chinese Medical Hospital, Liu Zhou 545001, ChinaDepartment of Endocrinology, People’s Hospital of Chongqing Banan District, Chongqing 401320, ChinaThis study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin). The PubMed, Web of Science, and National Library of Medicine databases were systematically searched from their inception until December 1, 2023. A meta-analysis was performed using Stata 15.1 software. A total of 12 studies with 13 outcome measures were included. The meta-analysis results revealed that liraglutide significantly reduced body mass index (mean difference [MD] = –1.06, 95%CI: –1.41, –0.70, p < 0.001), triglycerides (MD = –0.35, 95%CI: –0.61, –0.09, p = 0.0009), visceral adipose tissue (MD = –21.06, 95%CI: –34.58, –7.55, p = 0.002), and subcutaneous adipose tissue (MD = –20.53, 95%CI: –29.15, –11.90, p < 0.001) levels in patients with T2DM and NAFLD. Of the 11 studies, 2 reported the occurrence of adverse reactions, which were primarily gastrointestinal. Compared with placebo and other drugs (e.g., insulin), liraglutide may improve glucose metabolism, lipid and liver function parameters, and visceral and subcutaneous fat in patients with T2DM and NAFLD, thus constituting an effective treatment for these patients.https://www.jstage.jst.go.jp/article/endocrj/71/9/71_EJ24-0168/_html/-char/entype 2 diabetesliraglutidenon-alcoholic fatty liver |
| spellingShingle | Yuan-Yuan Xu Xu Wang Yu-Qing She Jie Liu Qing Zhang Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease Endocrine Journal type 2 diabetes liraglutide non-alcoholic fatty liver |
| title | Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease |
| title_full | Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease |
| title_fullStr | Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease |
| title_full_unstemmed | Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease |
| title_short | Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease |
| title_sort | meta analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non alcoholic fatty liver disease |
| topic | type 2 diabetes liraglutide non-alcoholic fatty liver |
| url | https://www.jstage.jst.go.jp/article/endocrj/71/9/71_EJ24-0168/_html/-char/en |
| work_keys_str_mv | AT yuanyuanxu metaanalysisoftheclinicalefficacyofliraglutideintreatingtype2diabetesmellituscomplicatedwithnonalcoholicfattyliverdisease AT xuwang metaanalysisoftheclinicalefficacyofliraglutideintreatingtype2diabetesmellituscomplicatedwithnonalcoholicfattyliverdisease AT yuqingshe metaanalysisoftheclinicalefficacyofliraglutideintreatingtype2diabetesmellituscomplicatedwithnonalcoholicfattyliverdisease AT jieliu metaanalysisoftheclinicalefficacyofliraglutideintreatingtype2diabetesmellituscomplicatedwithnonalcoholicfattyliverdisease AT qingzhang metaanalysisoftheclinicalefficacyofliraglutideintreatingtype2diabetesmellituscomplicatedwithnonalcoholicfattyliverdisease |